Patients must have histological or cytological confirmation of melanoma that is metastatic or unresectable and clearly progressive\r\n* NOTE: Any patient with BRAF V600 mutant melanoma (whether cutaneous, acral or mucosal primary) who meets the eligibility criteria is eligible for participation in this trial; patients with uveal melanoma are not eligible for this trial Patients with ocular melanoma. Ocular melanoma. Ocular melanoma Ocular melanoma Uveal melanoma is excluded Histopathologically confirmed diagnosis of metastatic or unresectable uveal melanoma or non-uveal melanoma harboring a GNAQ or GNA11 mutation; Note: For subjects with a diagnosis of uveal melanoma, documentation of mutation status for uveal melanoma will not be required prospectively given the high rate of GNAQ/11 mutations (> 90%) in this population Melanoma (excluding uveal melanoma); Subjects with melanoma or with a history of melanoma, invasive squamous cell carcinomas, or aphakia (due to contraindication for use of methoxsalen). Patients with melanoma of cutaneous, mucosal or acral-lentiginous origin or of unknown primary Melanoma Has Ocular Melanoma Patients with uveal melanoma will not be eligible as these tumors show low expression of GD3 Patients with ocular, mucosal and unknown primary melanoma will also be eligible History of uveal melanoma Metastatic melanoma eligible for {or currently o Rapidly progressing multi-focal metastatic melanoma Melanoma Study subjects previously treated with one of the peptides used in this trial, melanoma protein vaccine, melanoma whole cell vaccines, or with Montanide are not eligible Patients with primary ocular or mucosal melanoma are excluded Patients with melanoma arising from uveal/ocular primary sites. Prior melanoma vaccinations may be an exclusion criterion in the following circumstances:\r\n* Patients who have received, within the prior 5 years, melanoma vaccines or other vaccines containing an incomplete Freund’s adjuvant (IFA; such as montanide ISA-51).\r\n* Patients who have received any melanoma vaccine within the past 12 months.\r\n* Patients who have been vaccinated in the past with any of the melanoma peptides in the LPV7 vaccine included in this study. Patients must have a diagnosis of metastatic melanoma which is measurable either clinically or radiologically Patients with carcinomatosis meningitis or a history of ocular/uveal melanoma are excluded Phase 2 Cohort: ocular melanoma Participants must not have ocular melanoma Patients must have completely resected (as per standard of care) melanoma of cutaneous origin in order to be eligible for this study; patients must be classified as stage IIB or IIC cutaneous melanoma using the American Joint Committee on Cancer eighth edition; patients with melanoma of mucosal or other non-cutaneous origin are not eligible; patients with melanoma of ocular origin are not eligible Ocular melanoma Patients whose primary diagnosis was ocular melanoma Diagnosis of choroidal melanoma Melanoma located on face or digits Histologic diagnosis of metastatic uveal melanoma. Histologically or cytologically confirmed malignant melanoma from skin, or mucosal melanoma (i.e. ocular melanoma subjects are not eligible) Patients must have unresectable cutaneous, mucosal or ocular metastatic stage III/IV melanoma, and in the opinion of the institutional principal investigator (PI) is an acceptable candidate for adoptive cell therapy (ACT) with high dose interleukin-2 (IL-2); patients with ocular or mucosal metastatic melanoma may be included, as our prior experience indicates that TIL can be successfully propagated from these subtypes of melanoma metastases CAPMATINIB EXCLUSION CRITERIA: Uveal melanoma ENTRECTINIB EXCLUSION CRITERIA: Uveal melanoma Inclusion criteria Part 1: Safety run-in\n\n - Histologically confirmed, unresectable or metastatic melanoma with BRAF V600 mutation\n\n - Aspartate transaminase (AST) < 2.5× ULN and Alanine transaminase (ALT) < 2.5× ULN\n\n - ECOG performance status ? 1\n\n Part 2: Biomarker cohort\n\n - Histologically confirmed, unresectable or metastatic melanoma with BRAF V600 mutation\n\n - At least two cutaneous or subcutaneous or nodal lesions for tumor sample collection\n\n - ECOG performance status ? 2\n\n Part 3: Double-blind, randomized, placebo-controlled part\n\n - Histologically confirmed, unresectable or metastatic melanoma with BRAF V600 mutation\n\n - ECOG performance status ? 2\n\n Exclusion Criteria:\n\n Part 1: Safety run-in\n\n - Subjects with uveal or mucosal melanoma\n\n - Any history of CNS metastases\n\n - Prior systemic anti-cancer treatment for unresectable or metastatic melanoma\n\n - Prior loco-regional treatment for unresectable or metastatic melanoma in the last 6\n month\n\n - Prior neoadjuvant and/or adjuvant therapy for melanoma completed less than 6 months\n\n - Radiation therapy within 4 weeks prior to start of study treatment\n\n - Active, known, suspected or a documented history of autoimmune disease\n\n Parts 2 & 3: Biomarker cohort & double-blind, randomized, placebo-controlled part\n\n - Subjects with uveal or mucosal melanoma\n\n - Clinically active cerebral melanoma metastasis\n\n - Prior systemic anti-cancer treatment for unresectable or metastatic melanoma\n\n - Prior loco-regional treatment for unresectable or metastatic melanoma in the last 6\n month\n\n - Prior neoadjuvant and/or adjuvant therapy for melanoma completed less than 6 months\n\n - Radiation therapy within 4 weeks prior to start of study treatment\n\n - Active, known, suspected or a documented history of autoimmune disease\n\n Other protocol-defined Inclusion/Exclusion may apply. Histologically-confirmed primary uveal melanoma Metastatic uveal melanoma Histologic diagnosis of melanoma Ocular melanoma Metastatic uveal melanoma patients with bone-only disease 50% or less histologically or cytologically-proven ocular melanoma metastases in the parenchyma of the liver. Patients with advanced melanoma defined as unresectable stage III or metastatic stage IV disease. Patients with acral or mucosal melanoma or patients with unknown primary melanoma are acceptable in Phase 1b but are excluded from Phase II. Patients with uveal melanoma are excluded from the study. Patients must have metastatic melanoma, uveal melanoma or stage III in-transit or regional nodal disease (Turnstile I) Histologic diagnosis of stage IV metastatic melanoma, with 1 melanoma lesion that can be safely irradiated in the opinion of the radiation oncologist (note: subjects with primary ocular and mucosal melanoma are permitted). Lesions may include, but are not limited to: Melanoma of ocular primary Patient with detectable c-kit JM mutation confirmed by DNA or RNA sequencing, which is expected to be mainly found after screening of mucosal or acral melanoma or melanoma on skin with chronic sun-induced damages (defined by a microscopically marked elastosis involving the skin surrounding their primary melanoma) Measurable metastatic uveal melanoma Histologic diagnosis of metastatic melanoma Patients with uveal/ocular melanoma are excluded Histologically confirmed melanoma of cutaneous primary; metastatic melanoma from unknown primary are allowed Patients with melanoma of mucosal or ocular primary Mucosal melanoma and uveal melanoma are not allowed Has primary ocular melanoma Histologically or cytologically confirmed uveal melanoma that is metastatic or unresectable; if histologic or cytologic confirmation of the primary is not available, confirmation of the primary diagnosis of uveal melanoma by the treating investigator can be clinically obtained, as per standard practice for uveal melanoma; pathologic confirmation of diagnosis will be performed at the participating site Measurable metastatic ocular melanoma No prior anti-cancer treatment for melanoma (except surgery for the melanoma lesion(s) and/or except for adjuvant radiation therapy (RT) after neurosurgical resection for central nervous system (CNS) lesions) History of uveal melanoma Subjects must not have primary uveal or mucosal melanoma, history or evidence of melanoma associated with immunodeficiency states or history of other malignancy within the past 3 years. For Phase 2 expansion cohorts: Subjects with NSCLC, melanoma (checkpoint inhibitor naïve, primary refractory melanoma, relapsed melanoma), transitional cell carcinoma of the GU tract, SCCHN, ovarian cancer, MSI high CRC, RCC, DLBCL, and TNBC. Ocular melanoma is excluded. Patients must have completely resected melanoma of cutaneous origin or of unknown primary in order to be eligible for this study; patients must be classified as stage IIIA (N2a), IIIB, IIIC, or stage IV melanoma; patients with non-ulcerated T1b N1a disease are not eligible; patients with melanoma of mucosal or other non-cutaneous origin are eligible; patients with melanoma of ocular origin are not eligible; patients with a history of brain metastases are ineligible For melanoma: Uveal melanoma or LDH >1.1 x ULN Subjects with melanoma: Subject must not have primary ocular or mucosal melanoma, or history or evidence of melanoma associated with immunodeficiency states (eg, hereditary immune deficiency, organ transplant, or leukemia). Patients are excluded if they have known involvement of melanoma within the gastrointestinal tract Histologic or cytologic documentation of metastatic or Stage IIIc unresectable melanoma, with BRAFV600 mutation as assessed by BRAFV600 Mutation Test. Origin of the primary tumor may be of skin, mucosal, or acral locations but not of uveal origin. Participants having an unknown primary tumor may be eligible if uveal melanoma can be ruled out Uveal or ocular melanoma Ocular or uveal melanoma Subjects with ocular melanoma Histologically or cytologically confirmed diagnosis of unresectable or metastatic malignant melanoma, including cutaneous, ocular, mucosal and unknown primary tumour. Prior adjuvant melanoma therapy is permitted; any number of previous treatments for melanoma is permitted. Uveal or ocular MEL Patients must have measurable metastatic melanoma Primary uveal or mucosal melanoma Diagnosis of non-cutaneous melanoma or melanoma with unknown primary origin The patient has uveal melanoma. Mucosal melanoma and uvueal melanoma. Patients with ocular melanoma. Eligibility for pheresis: (Turnstile 1) Histopathologic documentation of melanoma concurrent with the diagnosis of metastatic disease. A diagnosis of uveal melanoma can be made clinically without primary tissue evaluation, based on history and records. A prior history of brachytherapy to the eye is sufficient clinical support for a diagnosis of uveal melanoma. Patient has uveal melanoma Patients diagnosed with advanced melanoma Desmoplastic or neurotropic melanoma. Subungual melanoma Primary ocular or mucosal melanoma Mucosal or ocular melanoma Histologic confirmation of advanced (metastatic or unresectable) uveal melanoma; if uveal melanoma has been diagnosed clinically and/or by gene expression profiling, patients may be included following discussion with the principal investigator Metastatic histologically or cytologically confirmed uveal melanoma with pathologic confirmation at a participating center that is judged to be progressive in the opinion of the treating physician; for the dose escalation portion of the trial only, patients with non-uveal melanoma harboring a GNAQ or GNA11 mutation will also be eligible Histopathologic documentation of melanoma concurrent with the diagnosis of metastatic disease Melanoma Uveal and mucosal melanoma Ocular melanoma Patients with metastatic uveal melanoma Group 4: Patients with NRAS mutated melanoma Uveal or mucosal melanoma Ocular melanoma Known mucosal or ocular melanoma or the presence of unresectable in-transit metastases. Prior systemic anti-cancer treatment and radiotherapy for melanoma; prior surgery for melanoma is allowed. Patients must have metastatic histologically or cytologically confirmed uveal melanoma; (if histologic or cytologic confirmation of the primary is not available, confirmation of the primary diagnosis of uveal melanoma by the treating investigator can be clinically obtained, as per standard practice for uveal melanoma); pathologic confirmation of diagnosis will be performed at Columbia University, Memorial Sloan-Kettering Cancer Center (MSKCC) or Vanderbilt University Medical Center Measurable metastatic melanoma with available autologous TIL Uveal melanoma with biopsy proven metastatic disease Patients who have a diagnosis for which a PD-(L)-1 inhibitor has been approved must have previously received treatment with one of these therapies. a. Melanoma Dose Expansion: Patients must have histologically confirmed metastatic melanoma (ocular melanoma not included) which has progressed on or after treatment with a PD-(L)1 inhibitor. Has a history of ocular melanoma Histological or cytological confirmed melanoma that is metastatic or unresectable; patients must have measurable disease (at least one measurable lesion) as defined by Response Evaluation Criteria In Solid Tumors (RECIST) criteria; NOTE: all sites of disease must be evaluated within 4 weeks prior to registration to treatment; patients must have a history of melanoma of one of the following subtypes: \r\n* Acral (as defined as occurring on the palms, soles, or subungual sites)\r\n* Melanoma arising from the vagina and/or vulva\r\n* Melanoma arising on other mucosal surface (not vagina or vulva) Patients must not have ocular melanoma Prior therapy for melanoma except surgery Histologic diagnosis of melanoma. Ocular Melanoma Melanoma of uveal origin Patients must have histologically or cytologically confirmed metastatic or locally recurrent uveal melanoma; because histologic or cytologic confirmation of primary uveal melanoma is not always possible, confirmation of the clinical diagnosis of uveal melanoma by the treating investigator is allowed; clinical diagnosis of uveal melanoma is often made by an ophthalmologist, not by tissue diagnosis; if an ophthalmologist diagnosed and treated a patient for uveal melanoma in the past, it is sufficient for a clinical diagnosis Primary Ocular Melanoma All melanomas, except ocular/uveal melanoma, regardless of primary site of disease will be allowed; mucosal melanomas are eligible. Patients with carcinomatosis meningitis or a history of ocular/uveal melanoma are excluded. Clinical diagnosis of primary uveal melanoma involving the posterior uveal tract in the study eye Planned enucleation or brachytherapy of the study eye due to uveal melanoma Uveal melanoma in the study eye originating in the anterior uveal tract (iris) Histologically or cytologically confirmed diagnosis of advanced or metastatic cutaneous melanoma that is determined to be BRAFV600 wild type and either NRAS wild type or NRAS mutation type. Note: Subjects with a melanoma of unknown primary origin may be allowed to enrol if all other types of melanoma (e.g., uveal, mucosal, or acral) can be reasonably ruled out. Patients must have metastatic histologically or cytologically confirmed uveal melanoma; if histologic or cytologic confirmation of the primary is not available, confirmation of the primary diagnosis of uveal melanoma by the treating investigator can be clinically obtained, as per standard practice for uveal melanoma; pathologic confirmation of metastatic disease will be performed at Memorial Sloan Kettering (MSK) or at a participating site Uveal Melanoma with liver metastasis Part A2 & B (RCC, NSCLC, HCC, and uveal melanoma): Have measurable disease as defined by RECIST v1.1. Patients must have histologically or cytologically confirmed metastatic uveal melanoma Melanoma of ocular origin Are at risk for melanoma due to having a first degree relative with a history of melanoma and/or at least 3 second or third degree relatives on the same side of the family with a history of melanoma and/or AIMS 1 AND 2: Healthy individuals with pigmented lesions or a partially biopsied melanoma or cutaneous melanoma metastasis whose treatment plan includes excision Patient must not have melanoma Histopathologically confirmed diagnosis of metastatic or unresectable malignant melanoma arising from skin. Ocular melanoma subjects are not eligible. Primary ocular or mucosal melanoma.